Save information for later
Sign Up

Learn About Lennox-Gastaut Syndrome (LGS)

What is the definition of Lennox-Gastaut Syndrome (LGS)?

Lennox-Gastaut syndrome is a severe condition characterized by repeated seizures (epilepsy) that begin early in life. Affected individuals have multiple types of seizures, developmental delays, and particular patterns of brain activity measured by a test called an electroencephalogram (EEG). An EEG shows a slow spike-and-wave pattern during wakefulness and generalized paroxysmal fast activity during sleep.

What are the causes of Lennox-Gastaut Syndrome (LGS)?

Lennox-Gastaut syndrome can have many different causes. The disorder likely has a genetic component, although the specific genetic factors are not well understood.

How prevalent is Lennox-Gastaut Syndrome (LGS)?

Lennox-Gastaut syndrome affects an estimated 1 to 2 per million people worldwide. This condition accounts for 3 to 4 percent of cases of epilepsy in children and 1 to 2 percent of cases in adults. For unknown reasons, it appears to be more common in males than in females.

Is Lennox-Gastaut Syndrome (LGS) an inherited disorder?

Most cases of Lennox-Gastaut syndrome are sporadic, which means they occur in people with no history of the disorder in their family. When Lennox-Gastaut syndrome is associated with a genetic change, the variant is usually not inherited but occurs as a random (de novo) event during the formation of reproductive cells (eggs or sperm) in an affected person's parent or during early embryonic development. However, 3 to 30 percent of people with this condition have a family history of some type of epilepsy, indicating that inherited genetic factors may play a role in some cases of Lennox-Gastaut syndrome.

Who are the top Lennox-Gastaut Syndrome (LGS) Local Doctors?
Pediatric Neurology | Pediatrics | Neurology
Pediatric Neurology | Pediatrics | Neurology

Ucsf Medical Group Business Services

400 Parnassus Ave, 
San Francisco, CA 
 (207.2 mi)
Languages Spoken:
English

Joseph Sullivan is a Pediatric Neurologist and a Pediatrics provider in San Francisco, California. Dr. Sullivan and is rated as an Elite provider by MediFind in the treatment of Lennox-Gastaut Syndrome (LGS). His top areas of expertise are Myoclonic Epilepsy, Dravet Syndrome, Epilepsy with Myoclonic-Atonic Seizures, and Epilepsy.

Ucsf Medical Group Business Services

400 Parnassus Ave, 
San Francisco, CA 
 (207.2 mi)
Languages Spoken:
English
Offers Telehealth

Robert Knowlton is a Neurologist in San Francisco, California. Dr. Knowlton and is rated as an Experienced provider by MediFind in the treatment of Lennox-Gastaut Syndrome (LGS). His top areas of expertise are Seizures, Epilepsy, Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE), Generalized Tonic-Clonic Seizure, and Deep Brain Stimulation.

 
 
 
 
Learn about our expert tiers
Learn More
Pediatrics | Neurology
Pediatrics | Neurology
10833 Le Conte Ave, 12-441 Mdcc, 
Los Angeles, CA 
 (455.2 mi)
Languages Spoken:
English

Raman Sankar is a Pediatrics specialist and a Neurologist in Los Angeles, California. Dr. Sankar and is rated as a Distinguished provider by MediFind in the treatment of Lennox-Gastaut Syndrome (LGS). His top areas of expertise are West Syndrome, Epilepsy, Spasmus Nutans, Seizures, and Deep Brain Stimulation.

What are the latest Lennox-Gastaut Syndrome (LGS) Clinical Trials?
Observational, Prospective, Multicenter Study of Epidyolex® (cannabidiol CBD 100 Mg/ml) Oral Solution, As Adjunctive Treatment for Seizures Associated with Lennox- Gastaut Syndrome (LGS), Dravet Syndrome (DS) and Tuberous Sclerosis Complex (TSC)

Summary: This is a prospective, observational study on approximately 70-100 Real World participants affected by LGS, DS, or TSC treated with Epidyolex® as prescribed in the summary of product characteristics. The eligible participants are expected to participate in the study for a duration of 52 weeks of treatment.

Match to trials
Find the right clinical trials for you in under a minute
Get started
An Open-Label Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adults with Either Classic Absence Epilepsy (with or Without Eyelid Myoclonia (EEM; Jeavons Syndrome), or Developmental Epileptic Encephalopathy (DEE).

Summary: The study is a pilot, open-label, study to test whether BMB-101 is safe and effective in reducing the frequency of seizures in subjects with Absence Epilepsy including Epilepsy with Eyelid Myoclonia (also called Jeavons Syndrome) as well as Developmental Epileptic Encephalopathies such as Dravet and Lennox Gastaut. The study will last up to 6 months. There will be a 1 month screening period, then ...

Who are the sources who wrote this article ?

Published Date: May 03, 2023
Published By: National Institutes of Health